Jasper Therapeutics, Inc. (NASDAQ:JSPR) Receives $74.86 Consensus Target Price from Brokerages

Shares of Jasper Therapeutics, Inc. (NASDAQ:JSPR - Get Free Report) have earned a consensus rating of "Buy" from the ten brokerages that are currently covering the company, MarketBeat reports. Ten equities research analysts have rated the stock with a buy recommendation. The average 12-month price objective among brokers that have covered the stock in the last year is $74.86.

Several analysts recently issued reports on JSPR shares. JMP Securities reissued a "market outperform" rating and issued a $70.00 price target on shares of Jasper Therapeutics in a research report on Tuesday. HC Wainwright reissued a "buy" rating and issued a $65.00 price target on shares of Jasper Therapeutics in a research report on Tuesday. BTIG Research started coverage on shares of Jasper Therapeutics in a research report on Monday, July 8th. They issued a "buy" rating and a $90.00 price target for the company. Cantor Fitzgerald reissued an "overweight" rating on shares of Jasper Therapeutics in a research report on Monday, September 9th. Finally, Royal Bank of Canada dropped their price objective on Jasper Therapeutics from $70.00 to $68.00 and set an "outperform" rating on the stock in a research note on Wednesday, August 14th.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in JSPR. StemPoint Capital LP purchased a new position in shares of Jasper Therapeutics during the first quarter worth about $3,794,000. Ikarian Capital LLC purchased a new position in shares of Jasper Therapeutics during the first quarter worth about $3,088,000. Russell Investments Group Ltd. purchased a new position in shares of Jasper Therapeutics during the first quarter worth about $2,343,000. Bank of New York Mellon Corp purchased a new position in shares of Jasper Therapeutics during the second quarter worth about $740,000. Finally, Concurrent Investment Advisors LLC purchased a new position in shares of Jasper Therapeutics during the first quarter worth about $599,000. Hedge funds and other institutional investors own 79.85% of the company's stock.

Jasper Therapeutics Trading Up 1.1 %

NASDAQ:JSPR traded up $0.21 on Friday, reaching $20.04. 645,428 shares of the stock traded hands, compared to its average volume of 164,404. The firm has a market capitalization of $301.88 million, a price-to-earnings ratio of -3.56 and a beta of 2.21. The company's 50 day moving average is $19.11 and its 200-day moving average is $21.48. Jasper Therapeutics has a 1-year low of $4.00 and a 1-year high of $31.01.

Jasper Therapeutics (NASDAQ:JSPR - Get Free Report) last released its earnings results on Tuesday, August 13th. The company reported ($0.97) earnings per share for the quarter, beating analysts' consensus estimates of ($1.09) by $0.12. On average, equities research analysts forecast that Jasper Therapeutics will post -4.16 EPS for the current fiscal year.

About Jasper Therapeutics

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.